Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation?
To identify and treat patients at high risk of cytomegalovirus (CMV) pneumonia after bone marrow transplantation (BMT), we tested for CMV viraemia weekly, and performed broncho‐alveolar lavage (BAL) on day 35 post‐transplant in 63 recipients. 36 allogeneic BMT recipients were at a high risk of CMV p...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 1997-07, Vol.98 (1), p.222-227 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 227 |
|---|---|
| container_issue | 1 |
| container_start_page | 222 |
| container_title | British journal of haematology |
| container_volume | 98 |
| creator | Ibrahim, A. Gautier, E. Roittmann, S. Bourhis, J.‐H. Fajac, A. Charnoz, I. Terrier, P. Salord, J‐M. Tancrède, C. Hayat, M. Bernaudin, J.‐F. Pico, J.‐L. |
| description | To identify and treat patients at high risk of cytomegalovirus (CMV) pneumonia after bone marrow transplantation (BMT), we tested for CMV viraemia weekly, and performed broncho‐alveolar lavage (BAL) on day 35 post‐transplant in 63 recipients. 36 allogeneic BMT recipients were at a high risk of CMV pneumonia (25 CMV‐seropositive recipients and 11 patients receiving marrow from a CMV‐seropositive donor). Patients with a positive BAL or viraemia received a 14 d course of ganciclovir or foscarnet. CMV was detected in 29 (46%) of the 63 BMT recipients and excretion of CMV in blood and BAL was significantly linked. However, among the 29 patients who excreted the virus, only 10 (35%) shed CMV in blood and BAL at the same time; 19 patients (65%) had detectable CMV in blood (11 patients) or BAL (eight patients) only. Therefore, on the basis of viraemia or BAL alone, 21/29 patients (70%) and 18/29 patients (60%), respectively, would have received antiviral treatment. BAL increased the CMV detection rate by 13% (8/63 patients) relative to viraemia. With this strategy, the incidence of CMV pneumonia was reduced to 3% in allografted patients. Only two of the 19 autografted patients developed fatal CMV pneumonia. We avoided anti‐CMV treatment in 54% of all the BMT recipients. In conclusion, CMV should be tested for in both blood and BAL fluid of BMT recipients at high risk of CMV pneumonia. |
| doi_str_mv | 10.1046/j.1365-2141.1997.1752987.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79156072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79156072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4795-57f26c3ca9ace7307d0dbaa6e8b1a085487eada034f04e8eef05cb45eac6245b3</originalsourceid><addsrcrecordid>eNqVkc2O0zAUhSMEGjoDj4B0hRC7FDuJ44QFI6gGBjSIBT9b68a5aVzcONhJZ_o6PCmuWnXPyrLOOdfn-kuSl5wtOSvKN5slz0uRZrzgS17XcsmlyOpKLh8eJYuz9DhZMMZkGiPV0-QyhA1jPGeCXyQXdZbnomaL5O_33s22Bb2f3JbWaN3O-DlAQzBRmKiFznkwAzRu6qGxzrWAQwuNd4PuHdodOYseLO5wTdDZ2bTgOhhxMjRMAXAChN6se_Am_D5Iq6-_YBxo3rrBIGA3kY_TB4Iteu_uYfI4hNHiMMUZbrh-ljzp0AZ6fjqvkp8fb36sbtO7b58-r97fpbqQtUiF7LJS5xpr1CRzJlvWNoglVQ1HVomikoQtsrzoWEEVUceEbgpBqMusEE1-lbw-zh29-zPH5dXWBE02NiE3ByVrLkoms2h8ezRq70Lw1KnRm1h-rzhTB0Bqow4U1IGCOgBSJ0DqIYZfnF6Zmy215-iJSNRfnXQMGm0XP0ObcLZlUjAheLS9O9rujaX9fxRQH77cxkv-DwESsDs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79156072</pqid></control><display><type>article</type><title>Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ibrahim, A. ; Gautier, E. ; Roittmann, S. ; Bourhis, J.‐H. ; Fajac, A. ; Charnoz, I. ; Terrier, P. ; Salord, J‐M. ; Tancrède, C. ; Hayat, M. ; Bernaudin, J.‐F. ; Pico, J.‐L.</creator><creatorcontrib>Ibrahim, A. ; Gautier, E. ; Roittmann, S. ; Bourhis, J.‐H. ; Fajac, A. ; Charnoz, I. ; Terrier, P. ; Salord, J‐M. ; Tancrède, C. ; Hayat, M. ; Bernaudin, J.‐F. ; Pico, J.‐L.</creatorcontrib><description>To identify and treat patients at high risk of cytomegalovirus (CMV) pneumonia after bone marrow transplantation (BMT), we tested for CMV viraemia weekly, and performed broncho‐alveolar lavage (BAL) on day 35 post‐transplant in 63 recipients. 36 allogeneic BMT recipients were at a high risk of CMV pneumonia (25 CMV‐seropositive recipients and 11 patients receiving marrow from a CMV‐seropositive donor). Patients with a positive BAL or viraemia received a 14 d course of ganciclovir or foscarnet. CMV was detected in 29 (46%) of the 63 BMT recipients and excretion of CMV in blood and BAL was significantly linked. However, among the 29 patients who excreted the virus, only 10 (35%) shed CMV in blood and BAL at the same time; 19 patients (65%) had detectable CMV in blood (11 patients) or BAL (eight patients) only. Therefore, on the basis of viraemia or BAL alone, 21/29 patients (70%) and 18/29 patients (60%), respectively, would have received antiviral treatment. BAL increased the CMV detection rate by 13% (8/63 patients) relative to viraemia. With this strategy, the incidence of CMV pneumonia was reduced to 3% in allografted patients. Only two of the 19 autografted patients developed fatal CMV pneumonia. We avoided anti‐CMV treatment in 54% of all the BMT recipients. In conclusion, CMV should be tested for in both blood and BAL fluid of BMT recipients at high risk of CMV pneumonia.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1046/j.1365-2141.1997.1752987.x</identifier><identifier>PMID: 9233590</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; blood detection ; bone marrow transplantation ; Bone Marrow Transplantation - adverse effects ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Bronchoalveolar Lavage Fluid - virology ; broncho‐ alveolar lavage detection ; cytomegalovirus ; Cytomegalovirus - isolation & purification ; Cytomegalovirus Infections - diagnosis ; Female ; Humans ; Leukemia - therapy ; Lymphoma - therapy ; Male ; Medical sciences ; Opportunistic Infections - diagnosis ; pneumonia ; Pneumonia, Viral - diagnosis ; Risk Factors ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Viremia - diagnosis</subject><ispartof>British journal of haematology, 1997-07, Vol.98 (1), p.222-227</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4795-57f26c3ca9ace7307d0dbaa6e8b1a085487eada034f04e8eef05cb45eac6245b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2141.1997.1752987.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2141.1997.1752987.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2750551$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9233590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ibrahim, A.</creatorcontrib><creatorcontrib>Gautier, E.</creatorcontrib><creatorcontrib>Roittmann, S.</creatorcontrib><creatorcontrib>Bourhis, J.‐H.</creatorcontrib><creatorcontrib>Fajac, A.</creatorcontrib><creatorcontrib>Charnoz, I.</creatorcontrib><creatorcontrib>Terrier, P.</creatorcontrib><creatorcontrib>Salord, J‐M.</creatorcontrib><creatorcontrib>Tancrède, C.</creatorcontrib><creatorcontrib>Hayat, M.</creatorcontrib><creatorcontrib>Bernaudin, J.‐F.</creatorcontrib><creatorcontrib>Pico, J.‐L.</creatorcontrib><title>Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation?</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>To identify and treat patients at high risk of cytomegalovirus (CMV) pneumonia after bone marrow transplantation (BMT), we tested for CMV viraemia weekly, and performed broncho‐alveolar lavage (BAL) on day 35 post‐transplant in 63 recipients. 36 allogeneic BMT recipients were at a high risk of CMV pneumonia (25 CMV‐seropositive recipients and 11 patients receiving marrow from a CMV‐seropositive donor). Patients with a positive BAL or viraemia received a 14 d course of ganciclovir or foscarnet. CMV was detected in 29 (46%) of the 63 BMT recipients and excretion of CMV in blood and BAL was significantly linked. However, among the 29 patients who excreted the virus, only 10 (35%) shed CMV in blood and BAL at the same time; 19 patients (65%) had detectable CMV in blood (11 patients) or BAL (eight patients) only. Therefore, on the basis of viraemia or BAL alone, 21/29 patients (70%) and 18/29 patients (60%), respectively, would have received antiviral treatment. BAL increased the CMV detection rate by 13% (8/63 patients) relative to viraemia. With this strategy, the incidence of CMV pneumonia was reduced to 3% in allografted patients. Only two of the 19 autografted patients developed fatal CMV pneumonia. We avoided anti‐CMV treatment in 54% of all the BMT recipients. In conclusion, CMV should be tested for in both blood and BAL fluid of BMT recipients at high risk of CMV pneumonia.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>blood detection</subject><subject>bone marrow transplantation</subject><subject>Bone Marrow Transplantation - adverse effects</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Bronchoalveolar Lavage Fluid - virology</subject><subject>broncho‐ alveolar lavage detection</subject><subject>cytomegalovirus</subject><subject>Cytomegalovirus - isolation & purification</subject><subject>Cytomegalovirus Infections - diagnosis</subject><subject>Female</subject><subject>Humans</subject><subject>Leukemia - therapy</subject><subject>Lymphoma - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Opportunistic Infections - diagnosis</subject><subject>pneumonia</subject><subject>Pneumonia, Viral - diagnosis</subject><subject>Risk Factors</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Viremia - diagnosis</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkc2O0zAUhSMEGjoDj4B0hRC7FDuJ44QFI6gGBjSIBT9b68a5aVzcONhJZ_o6PCmuWnXPyrLOOdfn-kuSl5wtOSvKN5slz0uRZrzgS17XcsmlyOpKLh8eJYuz9DhZMMZkGiPV0-QyhA1jPGeCXyQXdZbnomaL5O_33s22Bb2f3JbWaN3O-DlAQzBRmKiFznkwAzRu6qGxzrWAQwuNd4PuHdodOYseLO5wTdDZ2bTgOhhxMjRMAXAChN6se_Am_D5Iq6-_YBxo3rrBIGA3kY_TB4Iteu_uYfI4hNHiMMUZbrh-ljzp0AZ6fjqvkp8fb36sbtO7b58-r97fpbqQtUiF7LJS5xpr1CRzJlvWNoglVQ1HVomikoQtsrzoWEEVUceEbgpBqMusEE1-lbw-zh29-zPH5dXWBE02NiE3ByVrLkoms2h8ezRq70Lw1KnRm1h-rzhTB0Bqow4U1IGCOgBSJ0DqIYZfnF6Zmy215-iJSNRfnXQMGm0XP0ObcLZlUjAheLS9O9rujaX9fxRQH77cxkv-DwESsDs</recordid><startdate>199707</startdate><enddate>199707</enddate><creator>Ibrahim, A.</creator><creator>Gautier, E.</creator><creator>Roittmann, S.</creator><creator>Bourhis, J.‐H.</creator><creator>Fajac, A.</creator><creator>Charnoz, I.</creator><creator>Terrier, P.</creator><creator>Salord, J‐M.</creator><creator>Tancrède, C.</creator><creator>Hayat, M.</creator><creator>Bernaudin, J.‐F.</creator><creator>Pico, J.‐L.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199707</creationdate><title>Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation?</title><author>Ibrahim, A. ; Gautier, E. ; Roittmann, S. ; Bourhis, J.‐H. ; Fajac, A. ; Charnoz, I. ; Terrier, P. ; Salord, J‐M. ; Tancrède, C. ; Hayat, M. ; Bernaudin, J.‐F. ; Pico, J.‐L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4795-57f26c3ca9ace7307d0dbaa6e8b1a085487eada034f04e8eef05cb45eac6245b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>blood detection</topic><topic>bone marrow transplantation</topic><topic>Bone Marrow Transplantation - adverse effects</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Bronchoalveolar Lavage Fluid - virology</topic><topic>broncho‐ alveolar lavage detection</topic><topic>cytomegalovirus</topic><topic>Cytomegalovirus - isolation & purification</topic><topic>Cytomegalovirus Infections - diagnosis</topic><topic>Female</topic><topic>Humans</topic><topic>Leukemia - therapy</topic><topic>Lymphoma - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Opportunistic Infections - diagnosis</topic><topic>pneumonia</topic><topic>Pneumonia, Viral - diagnosis</topic><topic>Risk Factors</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Viremia - diagnosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ibrahim, A.</creatorcontrib><creatorcontrib>Gautier, E.</creatorcontrib><creatorcontrib>Roittmann, S.</creatorcontrib><creatorcontrib>Bourhis, J.‐H.</creatorcontrib><creatorcontrib>Fajac, A.</creatorcontrib><creatorcontrib>Charnoz, I.</creatorcontrib><creatorcontrib>Terrier, P.</creatorcontrib><creatorcontrib>Salord, J‐M.</creatorcontrib><creatorcontrib>Tancrède, C.</creatorcontrib><creatorcontrib>Hayat, M.</creatorcontrib><creatorcontrib>Bernaudin, J.‐F.</creatorcontrib><creatorcontrib>Pico, J.‐L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ibrahim, A.</au><au>Gautier, E.</au><au>Roittmann, S.</au><au>Bourhis, J.‐H.</au><au>Fajac, A.</au><au>Charnoz, I.</au><au>Terrier, P.</au><au>Salord, J‐M.</au><au>Tancrède, C.</au><au>Hayat, M.</au><au>Bernaudin, J.‐F.</au><au>Pico, J.‐L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation?</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>1997-07</date><risdate>1997</risdate><volume>98</volume><issue>1</issue><spage>222</spage><epage>227</epage><pages>222-227</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>To identify and treat patients at high risk of cytomegalovirus (CMV) pneumonia after bone marrow transplantation (BMT), we tested for CMV viraemia weekly, and performed broncho‐alveolar lavage (BAL) on day 35 post‐transplant in 63 recipients. 36 allogeneic BMT recipients were at a high risk of CMV pneumonia (25 CMV‐seropositive recipients and 11 patients receiving marrow from a CMV‐seropositive donor). Patients with a positive BAL or viraemia received a 14 d course of ganciclovir or foscarnet. CMV was detected in 29 (46%) of the 63 BMT recipients and excretion of CMV in blood and BAL was significantly linked. However, among the 29 patients who excreted the virus, only 10 (35%) shed CMV in blood and BAL at the same time; 19 patients (65%) had detectable CMV in blood (11 patients) or BAL (eight patients) only. Therefore, on the basis of viraemia or BAL alone, 21/29 patients (70%) and 18/29 patients (60%), respectively, would have received antiviral treatment. BAL increased the CMV detection rate by 13% (8/63 patients) relative to viraemia. With this strategy, the incidence of CMV pneumonia was reduced to 3% in allografted patients. Only two of the 19 autografted patients developed fatal CMV pneumonia. We avoided anti‐CMV treatment in 54% of all the BMT recipients. In conclusion, CMV should be tested for in both blood and BAL fluid of BMT recipients at high risk of CMV pneumonia.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>9233590</pmid><doi>10.1046/j.1365-2141.1997.1752987.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 1997-07, Vol.98 (1), p.222-227 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79156072 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences blood detection bone marrow transplantation Bone Marrow Transplantation - adverse effects Bone marrow, stem cells transplantation. Graft versus host reaction Bronchoalveolar Lavage Fluid - virology broncho‐ alveolar lavage detection cytomegalovirus Cytomegalovirus - isolation & purification Cytomegalovirus Infections - diagnosis Female Humans Leukemia - therapy Lymphoma - therapy Male Medical sciences Opportunistic Infections - diagnosis pneumonia Pneumonia, Viral - diagnosis Risk Factors Transfusions. Complications. Transfusion reactions. Cell and gene therapy Viremia - diagnosis |
| title | Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A37%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Should%20cytomegalovirus%20be%20tested%20for%20in%20both%20blood%20and%20bronchoalveolar%20lavage%20fluid%20of%20patients%20at%20a%20high%20risk%20of%20CMV%20pneumonia%20after%20bone%20marrow%20transplantation?&rft.jtitle=British%20journal%20of%20haematology&rft.au=Ibrahim,%20A.&rft.date=1997-07&rft.volume=98&rft.issue=1&rft.spage=222&rft.epage=227&rft.pages=222-227&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1046/j.1365-2141.1997.1752987.x&rft_dat=%3Cproquest_cross%3E79156072%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79156072&rft_id=info:pmid/9233590&rfr_iscdi=true |